Academica-e. Repositorio Institucional de la Universidad Pública de Navarra
Publication
Artículo científico (JournalArticle)
Endogenous α-Klotho is a common target in atherosclerosis and calcific aortic valve disease
Although atherosclerotic vascular disease (ASVD) and calcific aortic stenosis (AS) are distinct clinical entities, inflammation is a common driving force. The contribution of endogenous α-Klotho, an anti-aging protein, in the vasculature and aortic valve (AV) as an inflammatory mediator of such diseases remains unclear. We investigated α-Klotho expression using qPCR, ELISA, and immunohistochemistry in vascular (aorta, carotid, and femoral) and AV tissue samples from patients with ASVD (n = 112) and calcific AS (n = 172), respectively. We also determined circulating levels of soluble α-Klotho. We assessed α-Klotho associations with inflammatory and calcification markers. In vitro, we treated human vascular smooth muscle cells (VSMCs) and valve interstitial cells (VICs) with interleukin (IL)-1a and high-phosphate (HP) medium, respectively, and we evaluated the effects a-Klotho silencing and recombinant a-Klotho (rKlotho) supplementation. α-Klotho expression was significantly reduced in atherosclerotic vessels and stenotic AVs. Vascular expression varied across territories, with the lowest levels in the carotids. In stenotic AVs, α-Klotho expression was lower in fibro-calcified areas compared to "healthy" regions. Endogenous tissue α-Klotho and circulating soluble α-Klotho were inversely associated with local and systemic inflammatory markers and, in AVs, with osteogenic-related markers. In vitro, pro-inflammatory stimuli downregulated α-Klotho gene expression in VSMCs and VICs. α-Klotho silencing amplified inflammatory responses in both cell types and promoted VIC calcification, whereas rKlotho attenuated inflammation and inhibited osteogenic differentiation. These findings suggest endogenous α-Klotho plays a central role in the inflammation underlying ASVD and calcific AS., This work was supported by Instituto de Salud Carlos III (ISCIII) and co-funded by the European Union, Fondo Europeo de Desarrollo Regional, "Una manera de hacer Europa" (PI13/01736, PI16/00024, PI19/00035, PI21/01037, PI23/00168, PI24/01020, PI25/00057; RD21/0005/0013 -Plan de Recuperacion, ´ Transformacion ´ y Resiliencia. Union ´ Europea - NextGenerationEU-, RD24/0004/0022-ISCIII and co-funded by the European Union) and Departamento de Salud del Gobierno de Navarra (GNa01/21). E.M.N. is supported by a Sara Borrell fellowship (CD24/00070, ISCIII). A.G.L. is supported by a PFIS PhD studentship (FI22/00213, ISCIII). A.P.R. is supported by a contract from RICORS2040-RENAL (RD24/0004/0025, ISCIII and cofunded by the European Union). J.I. is supported by Ramon y Cajal Fellowship (RYC2023-043288-I). E.J. and J.D.C are supported by contracts from the Miguel Servet Programme (CP24/00091 and CP20/00122 respectively, ISCIII).
Project:
MINECO / Plan Estatal de Investigación Científica y Técnica y de Innovación 2017-2020 PI13-01736
,
MINECO / Plan Estatal de Investigación Científica y Técnica y de Innovación 2017-2020 PI16-00024
,
ISCIII / Plan Estatal de Investigación Científica PI19-00035
,
ISCIII / Técnica y de Innovación 2021-2023 PI21-01037
,
ISCIII / Plan Estatal de Investigación Científica PI23-00168
,
ISCIII / Técnica y de Innovación 2021-2023 PI24-01020
,
ISCIII / Plan Estatal de Investigación Científica PI25-00057
,
ISCIII / Técnica y de Innovación 2024-2027 RD21-0005-0013
,
ISCIII RD24-0004-0022
,
Gobierno de Navarra GNa01-21
View at: https://hdl.handle.net/2454/58341